Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nuvectis Pharma (NVCT) Net Income (2021 - 2026)

Nuvectis Pharma has reported Net Income over the past 6 years, most recently at -$6.0 million for Q1 2026.

  • Quarterly results put Net Income at -$6.0 million for Q1 2026, down 13.47% from a year ago — trailing twelve months through Mar 2026 was -$27.2 million (down 34.72% YoY), and the annual figure for FY2025 was -$26.4 million, down 39.17%.
  • Net Income reached -$6.0 million in Q1 2026 per NVCT's latest filing, up from -$7.3 million in the prior quarter.
  • Across five years, Net Income topped out at -$2.9 million in Q1 2022 and bottomed at -$7.5 million in Q3 2025.
  • Median Net Income over the past 5 years was -$5.9 million (2022), compared with a mean of -$5.5 million.
  • Peak annual rise in Net Income hit 39.9% in 2022, while the deepest fall reached 12695.65% in 2022.
  • Over 5 years, Net Income stood at -$6.7 million in 2022, then grew by 1.11% to -$6.6 million in 2023, then grew by 5.65% to -$6.2 million in 2024, then decreased by 17.06% to -$7.3 million in 2025, then increased by 17.28% to -$6.0 million in 2026.
  • Business Quant data shows Net Income for NVCT at -$6.0 million in Q1 2026, -$7.3 million in Q4 2025, and -$7.5 million in Q3 2025.